Deutsche Bank downgrades Novo Nordisk, sending shares down about 3%

Deutsche Bank cut its rating on Novo Nordisk and lowered its price target for the shares to 265 Danish kroner from 290 kroner, sending the stock down as much as 2.9% on Thursday ^[1]. The downgrade, led by analyst Emmanuel Papadakis, cites doubt that the company can return to growth in 2027 and concern about a looming patent cliff ^[1].

Novo Nordisk makes Ozempic and Wegovy, both semaglutide, and is the largest supplier of GLP-1 weight-loss and diabetes drugs in the US ^[1].

The bank pointed to what it called mixed second-quarter results and ongoing uncertainty about the company's mid-term revenue trajectory ^[1]. It also flagged limited upside from US Medicare prescriptions and the removal of ziltivekimab from the near-term earnings outlook, after that drug failed to reduce the risk of heart attack or stroke in a late-stage clinical trial ^[1].

Not every analyst reads that trial failure the same way. Citi has said the market's reaction to the ziltivekimab setback may be overdone because the drug was a minor contributor to Novo Nordisk's valuation, and it has kept a "neutral" rating on the stock, citing pricing pressure and increasing competition in the GLP-1 market ^[1].

The downgrade came roughly three weeks before Novo Nordisk's Capital Markets Day in London on September 21, which analysts now see as a critical event for management to address investor concerns and lay out its growth strategy, product pipeline and long-term outlook ^[1].

Not all of the recent news was negative. China's National Medical Products Administration has accepted Novo Nordisk's application to sell Wegovy in tablet form, and the application now moves into formal review ^[1]. JPMorgan estimates the weight-management GLP-1 market in China could grow to 30 billion yuan, about $4.1 billion, within five to seven years, up from 3 billion to 4 billion yuan today, as the country's overweight and obese population is projected to exceed 65% of the population by 2030 ^[1]. Eli Lilly submitted its application for its oral weight-loss drug orforglipron in late 2025 ^[1].

Novo Nordisk is also testing semaglutide in Alzheimer's disease, with full results expected around September 2026 ^[1]. In the US, its newest product is Wegovy HD, a once-weekly 7.2 mg semaglutide injection approved by the FDA in March 2026 to reduce excess body weight and maintain weight loss long term ^[2]. In the STEP UP trial, semaglutide 7.2 mg produced 20.7% mean weight loss in adults with obesity, and about one in three participants lost 25% or more; in the STEP UP T2D trial, adults with obesity and type 2 diabetes lost 14.1% on average ^[2]. Novo Nordisk has said the safety and tolerability profile of 7.2 mg was comparable to earlier semaglutide weight-management trials ^[2].

Why it matters for patients

A stock downgrade does not change which medicines are approved, how they are prescribed, or what an insurance plan covers. Novo Nordisk has not announced any change to the availability of Ozempic, Wegovy or Wegovy HD as a result of the downgrade, and no supply changes have been reported ^[1][2].

The factors Deutsche Bank and Citi cite — pricing pressure, Medicare prescription economics and competition from Eli Lilly — are the same forces that influence list prices, rebates and which products insurers steer patients toward ^[1]. That is why they matter beyond the trading floor, even though none of them changes a prescription today.

Pipeline depth also matters for people who need an option that fits them. Patients in the US already have both an injectable and an oral form of semaglutide: Wegovy is approved as a once-daily tablet (semaglutide 25 mg) and as weekly injections at 1.7 mg, 2.4 mg and 7.2 mg ^[2]. The Chinese application accepted by regulators covers the tablet form of Wegovy ^[1].

What the downgrade does not establish is whether Novo Nordisk plans to slow, cut or expand any specific research program. No such decision has been disclosed ^[1].

What happens next

• September 21, 2026: Novo Nordisk holds its Capital Markets Day in London, where management is expected to provide clarity on growth strategy and its long-term outlook ^[1].
• Around September 2026: full results are expected from testing of semaglutide in Alzheimer's disease ^[1].
• Second half of 2026: Novo Nordisk expects regulatory decisions in the EU and UK on semaglutide 7.2 mg in a single-dose pen ^[2].
• China's review of the oral Wegovy application is now in a formal process; no decision date has been disclosed ^[1].